Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab +/- Ipilimumab in Resectable HNSCC
NCT03700905Phase 3Unknown
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Aug 2018
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab, ipilimumab in head and neck squamous cell carcinoma (HNSCC), sponsored by University Medical Center Hamburg-Eppendorf. Status: unknown.
02
Drugs
nivolumabipilimumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03700905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03700905.